Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11299244 | PMC |
| http://dx.doi.org/10.1002/emp2.13263 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Xylazine-Associated Necrotic Upper-Extremity Wounds: A Single Hospital System's Experience with 82 Patients and 125 Wounds.
J Bone Joint Surg Am
December 2024
Philadelphia Hand to Shoulder Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Background: The rise in xylazine-adulterated heroin and fentanyl poses novel challenges to hand surgeons and a rising epidemic of necrotic upper-extremity wounds. While prior case studies have focused on particularly severe and complex xylazine-associated necrotic (XAN) wounds, the aim of this consecutive case series was to characterize the variability of presentations (ranging from mild to severe) at a single institution at the epicenter of the xylazine epidemic.
Methods: Patients presenting to a tertiary referral center for XAN upper-extremity wounds were retrospectively identified from emergency department visits and hospital admissions between January 2021 and December 2023.
Wound-associated agents in the unregulated drug supply: Evidence from a statewide drug checking program.
Int J Drug Policy
December 2024
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 1812 Ashland Avenue, 3rd Floor, Baltimore, MD 21205, USA.
Background: While the unregulated drug market has seen dramatic increases in fentanyl adulteration in the past decade, other adulterants have impacted the recent volatility of the drug supply. There has been recent documentation related to the presence of wound-associated substances; however, there is a lack of data showing the prevalence of these substances across unregulated drug market samples over time. The aim of this paper is to examine known and potential wound-associated agents' (xylazine, levamisole, medetomidine) prevalence in Maryland's unregulated drug supply.
View Article and Find Full Text PDFDoor-to-door overdose harm reduction: an Illinois case study.
Harm Reduct J
December 2024
Buehler Center for Health Policy and Economics, Institute for Public Health and Medicine, Northwestern University, 420 E. Superior St. 9th Floor, Chicago, IL, 60611, USA.
Article Synopsis
- Harm reduction for people who use drugs (PWUD) is a key strategy in US drug policy, focusing on meeting communities’ needs and providing various support services.
- The Block-by-Block (BXB) intervention, launched in 2022 across five pilot areas in Illinois, aims to distribute naloxone and drug test strips in private or neutral settings to reduce opioid-related fatalities.
- Early results show that the BXB initiative is feasible, with a 55% response rate at homes approached, and high acceptability, as 75% of those who answered were supportive of the intervention.
First Detection of Xylazine in Texas Wastewater and Its Association with Fentanyl Use.
medRxiv
November 2024
Department of Environmental and Occupational Health Sciences, University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.
Article Synopsis
- The United States is facing a worsening drug overdose crisis, with xylazine—an animal sedative—emerging as a significant threat in the illicit drug market.
- A study in El Paso, Texas, used wastewater analysis to monitor xylazine presence and its potential link to fentanyl use over 14 months, finding xylazine in most treatment plants sampled.
- The research indicated a direct correlation between xylazine and higher fentanyl levels, urging the need for improved monitoring and targeted health interventions in communities impacted by the opioid epidemic.
Exploring Human Misuse and Abuse of Veterinary Drugs: A Descriptive Pharmacovigilance Analysis Utilising the Food and Drug Administration's Adverse Events Reporting System (FAERS).
Toxics
October 2024
Medical School, The Grove, Swansea University, Singleton Campus, Wales SA2 8PP, UK.
Introduction: Evidence suggests an increasing misuse of veterinary medicines by humans. This study aims to analyse Adverse Events (AEs) associated with selected veterinary products using the Food and Drug Administration Adverse Events Reporting System (FAERS).
Methods: A descriptive pharmacovigilance analysis was conducted on AEs related to 21 drugs approved for human and/or animal use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!